Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopason in moderately severe Parkinson's disease
NCT07572071Phase 1Recruiting
- Sponsor
- Royan Institute
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Dopacell in Parkinson's disease (PD), sponsored by Royan Institute. Primary endpoints: Safety at 12 months and Feasibility at 12 months. Started Aug 2025; status: recruiting.
02
Drugs
Dopacell
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07572071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572071.